Kennedy Capital Management LLC Cuts Stock Position in Eli Lilly and Company $LLY

Kennedy Capital Management LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 18.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 29,448 shares of the company’s stock after selling 6,786 shares during the period. Kennedy Capital Management LLC’s holdings in Eli Lilly and Company were worth $22,469,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Rehmann Capital Advisory Group increased its holdings in Eli Lilly and Company by 1.1% in the 3rd quarter. Rehmann Capital Advisory Group now owns 4,733 shares of the company’s stock worth $3,612,000 after acquiring an additional 50 shares in the last quarter. Nelson Capital Management LLC lifted its holdings in Eli Lilly and Company by 26.5% during the third quarter. Nelson Capital Management LLC now owns 4,697 shares of the company’s stock valued at $3,584,000 after purchasing an additional 984 shares in the last quarter. Certuity LLC grew its position in shares of Eli Lilly and Company by 9.8% in the third quarter. Certuity LLC now owns 5,694 shares of the company’s stock valued at $4,345,000 after purchasing an additional 508 shares during the period. South Plains Financial Inc. purchased a new stake in shares of Eli Lilly and Company during the third quarter worth about $321,000. Finally, Tocqueville Asset Management L.P. increased its stake in shares of Eli Lilly and Company by 1.6% during the third quarter. Tocqueville Asset Management L.P. now owns 24,398 shares of the company’s stock worth $18,616,000 after purchasing an additional 394 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Medicare access expansion for tirzepatide drugs (Zepbound, Mounjaro) broadens insured demand and reduces out-of-pocket barriers, supporting near-term volume growth. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Large international capacity investments — most notably a $3B China manufacturing commitment plus separate Korea and Japan investments — reduce supply risk, support local pricing flexibility, and position Lilly to capture rapid GLP‑1 market growth in APAC. Lilly to Invest $3 Billion in China to Boost Obesity Pill
• Positive Sentiment: Pipeline and commercial initiatives remain growth drivers: the company is filing/launching oral GLP‑1 orforglipron (mid‑2026 target) and promoting Employer Connect / LillyDirect to expand employer coverage — potential to materially increase addressable market and volumes if uptake continues. Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand
• Neutral Sentiment: Analyst and market narrative remains bullish on long‑term GLP‑1 dominance (strong buy calls, elevated price targets) even as management guides for slower but still robust EPS growth — supports long‑term thesis but keeps expectations high. Eli Lilly: The Weight-Loss Craze Isn’t Over
• Negative Sentiment: Safety/regulatory overhang — Lilly flagged a concerning unknown impurity in compounded (non‑commercial) tirzepatide mixed with vitamin B12; that warning could prompt tighter scrutiny of compounding practices and consumer caution, and generate negative headlines or enforcement actions. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Near-term market psychology and trading momentum concerns: some commentators warn the GLP‑1 euphoria and LLY’s price action have weakened since late 2025, raising risk of multiple compression or short‑term pullbacks despite solid fundamentals. Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November

Eli Lilly and Company Price Performance

LLY traded up $18.38 during trading on Friday, reaching $995.63. The company’s stock had a trading volume of 384,265 shares, compared to its average volume of 3,150,500. The company has a market cap of $940.69 billion, a price-to-earnings ratio of 43.36, a PEG ratio of 1.16 and a beta of 0.40. The firm has a fifty day simple moving average of $1,039.17 and a two-hundred day simple moving average of $947.29. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter last year, the firm earned $5.32 earnings per share. The business’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on LLY shares. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Morgan Stanley restated an “overweight” rating and issued a $1,313.00 target price on shares of Eli Lilly and Company in a research report on Thursday, March 5th. HSBC reiterated a “hold” rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 2nd. Finally, Leerink Partners raised their price objective on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.